Treatment for Neoplasm Metastasis

Patients with neoplasm metastasis have lower QOL than patients with advanced stage disease, which is similar to other patients. Most patients would be eligible for adjuvant treatment during relapse.

Overall, treatments for metastatic neoplasm (neoplasm metastasis) are not different from treatment for primary neoplasm (neoplasm tumor) in clinical characteristics. It is necessary to clarify what will affect therapeutic effect by neoplasm metastasis on the treatment outcome of systemic therapy for local and metastatic neoplasm.

Neoplasm's metastatic rate is much higher than expected when the age was young. Most cancers occurred in individuals 25–64 years (54%). Advanced age was the primary cause of neoplasm metastasis.

The metastatic processes play an important role in cancer. In addition to primary cancers in patients with metastatic cancers, an increased incidence of metastases in metastatic cancers was found. A possible causal relationship between primary cancers and metastases was indicated.

Nearly 6 million Americans are expected to develop cancer-derived metastasis in the next 5 years, and these estimates may be over-estimated given the limitations inherent in the current American Cancer Society and United States Preventive Service Task Force estimates and the high-risk nature of cancer-derived metastasis. These numbers should be considered along with the fact that cancers thought to be at the upper end of the disease spectrum are very rare and require particular vigilance.

Neoplasm metastasis can be preceded by local and system dissemination or by dissemination after surgery, particularly in the postoperative period, or by local dissemination without dissemination and in rare cases, it is only local. Different mechanisms contribute to neoplasm metastasis. Oncological surgery may compromise the elimination of neoplasm dissemination.

Cough, chest pain and dyspnea are the most common signs of cancer. The combination of these three can contribute to the early diagnosis of cancer.

It is likely that, although neoplasm metastasis might be cured, it would come back or metastasize again. We advise all patients with an aggressive neoplasm disease to seek neoplasm metastasis for early diagnosis in an oncologically competent hospital.

The number of clinical trials for treatment had significantly increased between 2000 and 2011, suggesting a growth in treatment. A systematic review of the clinical trials concluded that the available evidence does not support the use of any particular treatment apart from conventional therapy and supportive care.

In our experience, the presence of one of the following criteria: female; a breast cancer, prostate cancer or a malignant tumor of the skin. It's crucial that the patient and the doctor are aware that at any time the patient could evolve an asymptomatic, insidious and deadly metastatic neoplasm; thus it is important to seek in its latest stages a doctor able to perform the proper imaging diagnostic tests.

The majority of primary cancer patients developed metastases. The most frequent sites of primary cancers were (in descending order of frequency): oral cavity; breast; lung; colon; thyroid; gastric; prostate; and prostate and other sites. The incidence of metastatic breast and oral cancers were similar. However, we observed that only 11% of the patients presenting a breast tumor had metastatic disease and only 0.3% had metastatic gastric cancer. Data from a recent study could be explained by an overestimation of the incidence of these metastases. Moreover, we found that only 2% of colorectal tumors were metastatic, whereas more than 20% of primary adenocarcinoma of the intestinal transit were metastatic.